Cara Therapeutics Inc logo

Cara Therapeutics Inc Share Price Today (NASDAQ: CARA)

Cara Therapeutics Inc share price is $0 & ₹0.00 as on 13 Apr 2025 IST

▲

-15.96

(-100%)

Market is closed - opens 7 PM, 30 Jun 2025

Bell Icon

The stock has been delisted from the stock exchange on 14 Apr 2025

View live Cara Therapeutics Inc share price in Dollar and Rupees. Guide to invest in Cara Therapeutics Inc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cara Therapeutics Inc, along with analyst recommendations, forecasts, and comprehensive financials.

Cara Therapeutics Inc (CARA) Key Statistics

in dollars & INR

Previous Close
$15.96
Open
$5.39
Market Capitalization
$25.4M
Today's Volume
$237.1K
Revenue TTM
$7.1M
EBITDA
$-55.6M
Earnings Per Share (EPS)
$-15.53
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-270.01%

How to invest in Cara Therapeutics Inc Stock (CARA) from India?

It is very easy for Indian residents to invest directly in Cara Therapeutics Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cara Therapeutics Inc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cara Therapeutics Inc or CARA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cara Therapeutics Inc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cara Therapeutics Inc shares which would translate to null fractional shares of Cara Therapeutics Inc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Cara Therapeutics Inc, in just a few clicks!

Global Institutional Holdings in Cara Therapeutics Inc

  • Vanguard Group Inc

    0.31%

  • Rockefeller Capital Management L.P.

    0.28%

  • Farallon Capital Management, L.L.C.

    0.24%

  • Susquehanna International Group, LLP

    0.21%

  • Renaissance Technologies Corp

    0.17%

  • Shay Capital LLC

    0.16%

Analyst Recommendation on Cara Therapeutics Inc

Rating
Trend

Buy

    81%Buy

    18%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Cara Therapeutics Inc(by analysts ranked 0 to 5 stars)

CARA Cara Therapeutics Inc Financials in INR & Dollars

Revenue
Profit
Cash Flow
Annually
Quarterly
FY19
FY20
FY21
FY22
FY23
FY24
FY24Y/Y Change
Revenue
$7.1M
↓ 65.96%
Net Income
$-70.9M
↓ 40.2%
Net Profit Margin
-992.95%
↓ 427.74%

About Cara Therapeutics Inc

Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Organization
Cara Therapeutics Inc
Employees
10
CEO
Mr. Christopher A. Posner
Industry
Health Technology

Management People of Cara Therapeutics Inc

NameTitle
Mr. Christopher A. Posner
President, CEO & Director
Mr. Ryan D. Maynard
Chief Financial Officer
Mr. Scott M. Terrillion J.D.
Chief Compliance Officer, General Counsel & Corporate Secretary
Mr. Matthew Murphy
Manager of Investor Relations

Important FAQs about investing in CARA Stock from India :

Can Indians buy Cara Therapeutics Inc shares?

Yes, Indians can invest in the Cara Therapeutics Inc (CARA) from India.

With INDmoney, you can buy Cara Therapeutics Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Cara Therapeutics Inc at zero transaction cost.

How can I buy Cara Therapeutics Inc shares from India?

It is very easy to buy Cara Therapeutics Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cara Therapeutics Inc (CARA) be purchased?

Yes, you can buy fractional shares of Cara Therapeutics Inc with INDmoney app.

What are the documents required to start investing in Cara Therapeutics Inc stocks?

To start investing in Cara Therapeutics Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Cara Therapeutics Inc?

Today's market capitalisation of Cara Therapeutics Inc CARA is 25.4M

Who is the Chief Executive Officer (CEO) of Cara Therapeutics Inc ?

Mr. Christopher A. Posner is the current Chief Executive Officer (CEO) of Cara Therapeutics Inc.